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Do low-grade and low-volume prostate cancers bear the 
hallmarks of malignancy?
Hashim Uddin Ahmed, Manit Arya, Alex Freeman, Mark Emberton
Prostate cancer is generally multifocal and consists of a dominant focus—measured by tumour volume and deemed 
the index lesion—and one or more separate, secondary tumour foci of smaller volume. Much laboratory and clinical 
evidence has shown that we need to rethink how we regard low-grade and low-volume prostate lesions. In this 
Personal View, we discuss why small, low-grade Gleason pattern prostate lesions, which are currently designated as 
prostate cancer, could be regarded as non-malignant. These lesions either do not meet the criteria of the hallmarks of 
cancer or robust evidence that they do so is absent, by contrast with large lesions with a high Gleason grade, which 
seem to cause most metastatic disease.
Introduction
Diagnosis and treatment of localised prostate cancer has 
been a much debated topic and as such is fraught with 
controversy. This situation has not been helpful for men 
who are at risk of prostate cancer or who have been 
diagnosed with the disease.1 The issues have been well 
described: over diagnosis, underdiagnosis, missed diag-
nosis, misclassi ﬁ cation of risk, overtreatment, and 
under treatment. Despite a general acceptance that these 
issues are both real and important, few recommendations 
have been suggested to help to mitigate them.
One approach that merits some discussion is the 
reclassiﬁ cation of the generic term prostate cancer 
(when applied to disease localised to the prostate) into 
two subtypes—one that can be safely ignored, or better, 
not diagnosed and another that, if left untreated, would 
compromise either quality or quantity of life. Possible 
beneﬁ ts of not diagnosing a lesion that is unlikely to 
aﬀ ect a patient’s life include reduction of the anxiety of 
living with a cancer diagnosis and avoidance of potential 
radical surgery that might not be of clinical beneﬁ t 
and could cause substantial side-eﬀ ects. Even active 
surveillance would incur costs to the health-care 
system and the patient through additional clinical visits 
and biopsies.
Such a proposal is not totally new. A US National 
Institutes of Health and National Cancer Institute expert 
group meeting on active surveillance2 stated that 
“because of the very favorable prognosis of low-risk 
prostate cancer, strong consideration should be given to 
removing the anxiety-provoking term ‘cancer’ for this 
condition”. Add itionally, Esserman and colleagues3 have 
argued that “minimal risk lesions should not be called 
cancer”, with these lesions perhaps instead being called 
“indolent lesions of epithelial origin (IDLE)”. Others 
have oﬀ ered similar opinions in the past year.4,5
Not all prostate cancers are destined to progress
The future behaviour of lesions that are identiﬁ ed early 
in the natural history of several cancers remains 
uncertain. Some will regress, others will remain stable, 
some will seem stable because of very long cell-
doubling times, and a few will progress. Although lung 
cancer is one of the most lethal cancers in terms of the 
ratio of diagnoses to cancer-speciﬁ c deaths, one in six 
individuals who die of causes other than lung cancer 
will have apparently malignant lesions at autopsy; these 
lesions are now termed pseudodisease in recognition of 
their non-malignant behaviour. Had these lesions been 
diagnosed during life rather than at autopsy, treatment 
would have resulted, but with little beneﬁ t to the patient 
and some harms and costs.6 Thyroid cancer is closer to 
prostate cancer in terms of the burden of subclinical 
disease. The autopsy frequency of cancers in the thyroid 
gland in people who have died from causes other than 
thyroid cancer is one in two. This situation has led to 
such lesions being labelled papillary microcarcinoma.7 
Similarly, a National Institutes of Health consensus 
statement suggested that ductal carcinoma in situ of 
the breast should drop the word carcinoma from its 
name for the same reason.8 Urologists and uro-
pathologists are familiar with these issues. An 
increasing recognition that progression, metastases, 
and death are rare events in small renal masses has led 
to similar discussion about whether such lesions 
should also be deemed pseudo disease.9 Low-risk, non-
invasive bladder lesions have also been successfully 
reclassiﬁ ed from bladder cancer to papillary urothelial 
neoplasia of low malignant potential.10
We believe, as do many others, that it is time to 
apply the same reasoning to low-risk prostate cancer. 
Prostate cancer is generally multifocal and consists of a 
dominant focus (as measured by tumour volume), 
deemed the index lesion, and one or more separate, 
secondary tumour foci of smaller volume (ﬁ gure 1). 
Much laboratory and clinical evidence has shown that 
we need to rethink the nomenclature we apply to low-
grade and low-volume lesions.11 We believe that small, 
low-grade Gleason pattern lesions, which are currently 
designated as prostate cancer, could be regarded as non-
malignant. Using the framework provided by Hanahan 
and Weinberg,12 we argue that these lesions either do not 
meet the criteria of the six hallmarks of cancer, or robust 
evidence that they do so is absent, by contrast with 
larger, high-grade lesions, which seem to cause most 
metastatic disease.
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The changing face of Gleason grading
In 1966, Donald Gleason ﬁ rst published his unique 
grading system for prostate cancer based solely on the 
architectural pattern of the tumour.13 He developed a 
5-point scale on the basis of the outcomes of 270 patients, 
in which patterns 1, 2, and 3 represented tumours that 
most closely resembled healthy prostatic glands, and 
patterns 4 and 5 represented tumours (or parts of 
tumours) that were increasingly anaplastic in appearance 
(ﬁ gure 2, table).14 An innovative aspect of this system was 
that, rather than assigning the worst grade as the grade 
of the carcinoma, the sum of the two most common 
patterns is calculated and reported as the Gleason sum 
score. For example, an area with predominantly pattern 3 
disease and a small area of pattern 4 would be designated 
as Gleason 3 + 4 = 7. Since the Gleason system was 
introduced, pathologists have adopted modiﬁ cations to 
the original grading system as described, to adapt it to 
modern needs (table).
Redesignation of cancer to non-cancer within the 
Gleason system is not new. The original 5-point ordinal 
scale described by Gleason is now rarely used. Instead, 
the scale starts at 3 and ends at 5—something that all 
clinicians struggle with when trying to explain it to 
patients. Gleason patterns 1 and 2, originally described by 
Gleason as changes consistent with malignant trans-
formation, are now regarded as normal variants of the 
prostate architecture.15 The redesignation of Gleason 
pattern 3 (possibly qualiﬁ ed by an upper threshold on 
volume) could be the next incremental step on a 
40-year process of reﬁ nement of the Gleason classiﬁ cation 
system. For example, there has been an accepted grading 
shift upwards—one element of the so-called Will Rogers 
phenomenon16—with the changing deﬁ nition of Gleason 
pattern 4 resulting in the regrouping of cases previously 
regarded as Gleason score 6 into the Gleason score 7 
classiﬁ cation. In many cases of cancer in which the 
patterns would previously have been assigned to the 
lowest Gleason pattern 1, advances in immuno-
histochemistry have shown the presence of basal cells, 
identifying such cases as atypical adenomatous 
hyperplasia, a benign mimic of cancer.17 Moreover, lesions 
with patterns 1 and 2 have been recognised as biologically 
similar to pattern 3, further discouraging their use (table).
Hallmark one: self-suﬃ  ciency in growth signals
Tumour cells can generate their own growth signals and 
reduce their dependence on stimulation from the 
surrounding normal tissue microenvironment.
Ross and colleagues18 used laser capture microdissection 
to extract cells from radical prostatectomy specimens 
from 23 men to create two subgroups, those with either 
exclusive Gleason pattern 3 (Gleason score 6) or those 
with exclusive pattern 4 (Gleason score 8). The inves-
tigators measured mRNA expression of 18 344 unique 
genes in the extracted cells, and noted diﬀ erential 
expression of 670 of these genes between Gleason pattern 
3 and Gleason pattern 4 lesions. The genes that were 
exclusively expressed in the pattern 4 tumours corres-
ponded to those that are upregulated in embryonic, 
neuronal, and haemopoietic stem cells. Importantly, 
among these were EGF and EGFR. Overexpression of 
both of these genes is associated with independent cell 
proliferation and enhanced cell motility through several 
signal transduction mechanisms, including the MAPK, 
AKT, and RAS pathways. As well as the upregulation of 
EGFR, the investigators showed overexpression of 
MAP2K4 and the EGF-activated promigratory gene 
RALA, and downregulation of REPS2 (which negatively 
regulates EGFR via endocytosis), PHLPP, and PML (both 
of which inactivate the protein kinase phospho-AKT, 
which mediates growth-factor associated cell survival) in 
Gleason pattern 4 lesions.
Skacel and colleagues19 used a tissue microarray 
of more than 300 tissue cores derived from radical 
prostatectomy specimens to show that HER2/neu proto-
oncogene ampliﬁ cation, as measured by ﬂ uorescent in 
situ hybridisation, was associated with high tumour 
volume of greater than 2·0 cm³ (p=0·004). Ampliﬁ cation 
of HER2/neu, a member of the EGFR family, was almost 
exclusively conﬁ ned to Gleason pattern 4 lesions rather 
than Gleason pattern 3 lesions.
Hallmark two: insensitivity to antigrowth 
signals
Cancer cells must be able to resist the normal antigrowth 
signals that push them into a quiescent phase of the cell 
cycle or enter into postmitotic phases that ensure 
speciﬁ c cell diﬀ erentiation.
Figure 1: Hallmarks of cancer as applied to the index and secondary lesions in prostate cancer
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The D-type cyclins are associated with the regulation of 
transition from G1 to S phase during the cell cycle. Cyclin 
D2 is a direct target of MYC and it sequesters CDKN1B 
(p27Kip1), a cell cycle inhibitor), which subse quently results 
in entry to the cell cycle.20 Inactivation of cyclin D2 might 
be caused by aberrant promoter hypermethylation.
Using 101 radical prostatectomy specimens, Padar and 
colleagues21 reported that maximum Gleason pattern 3 
lesions had signiﬁ cantly greater frequencies of cyclin 
D2 methylation than did those that contained Gleason 
patterns 4 or 5. Transforming growth factor β (TGFβ) can 
impede growth by the induction of inhibitors of cyclin-
dependent kinases, including CDKN1B. Also using 
radical prostatectomy specimens, Guo and colleagues22 
showed that there is progressively di minished CDKN1B 
immunostaining with increasing Gleason score in 
prostate neoplasms. All Gleason pattern 5 foci were 
completely negative for CDKN1B staining, which 
suggests that these cells are unresponsive to the growth-
inhibitory eﬀ ect of TGFβ. This loss of CDKN1B was 
associated with an increase in the proliferative index of 
high-grade prostate cancers.
Hallmark three: resisting cell death
The ability of cancer cells to resist programmed cell 
death (apoptosis) is key to ensuring continued growth 
and proliferation.
True and colleagues23 used laser capture microdissection 
to acquire speciﬁ c subpopulations of prostate cancer 
cells consistent with lesions containing Gleason 
patterns 3, 4, and 5 from 29 radical prostatectomy 
specimens. They proﬁ led transcript abundance using 
cDNA micro array analysis and developed an 86-gene 
model capable of diﬀ erentiating between lesions that 
contain Gleason pattern 3 and those that contain higher 
patterns (4 and 5). This model was 76% accurate in 
characterising an independent set of 30 primary prostate 
lesions. One speciﬁ c discriminatory gene identiﬁ ed was 
DAD1, a gene encoding defender against cell death 1, 
which is a downstream target of the NFκB survival 
pathway and displays an antiapoptotic function. DAD1 
protein ex pression was measured by immuno-
histochemistry in tissue microarrays consisting of 
formalin-ﬁ xed radical prostatectomy tissue from 
131 benign and 306 pre sumed cancerous samples. 
DAD1 protein concentrations showed a strong 
association with Gleason grade, with tumours of 
patterns 4 and 5 more likely to stain intensely compared 
with Gleason pattern 3.
Another more familiar antiapoptotic gene is BCL2, 
the role of which in carcinogenesis and castrate resist-
ance in prostate cancer is well established. Fleischmann 
and colleagues24 did immunohistochemical analysis 
on a tissue microarray of 3261 radical prostatectomy 
specimens and reported that BCL2 expression was 
signiﬁ cantly upregulated in lesions with a high Gleason 
score (lesions that included Gleason patterns 4 and 5) 
compared with those that were only pattern 3.
Hallmark four: unlimited replicative potential
Mammalian cells seem to have an inherent autonomous 
function, independent of cell-to-cell signalling, that 
limits their replicative ability. Cancers disrupt this 
intrinsic pathway.
Cells that transform into cancer have to be able to subvert 
this so-called brake on replication. We have some evidence 
that exclusive Gleason pattern 3 prostate lesions have this 
brake preserved and that high-grade cancers are more 
likely to have evolved a mechanism to overcome it. 
Tomlins and colleagues25 provided some of this evidence 
from their well designed experiments. They used radical 
prostatectomy specimens (101 micro dissected specimens 
from 44 individuals) to develop two phenotype tissue 
pools—one low-risk (exclusive Gleason pattern 3) and one 
high-risk (Gleason pattern 4 or higher). The high Gleason 
grade lesions showed decreased androgen signalling, 
similar to metastatic prostate cancer, which could reﬂ ect 
dediﬀ erentiation and account for the clinical association 
of the grade of the high-grade lesions with prognosis. This 
ﬁ nding was also reported by Hendriksen and colleagues,26 
who noted lower androgen signalling in high-grade 
Gleason pattern prostate cancer than in low-grade Gleason 
pat tern lesions. The researchers suggested that localised 
prostate cancer cells become more aggressive by selectively 
downregulating androgen-responsive genes, which 
results in increased tumour cell replication and pro-
liferation, dediﬀ erentiation, or reduced apoptosis.
Another mechanism that is available to the cell to 
overcome the intrinsic brake on replication is gene 
translocation. The TMPRSS2–ERG translocation is one of 
the most prevalent genetic changes in prostate cancer, the 
presence of which results in overexpression of the ERG 
transcription factor, and therefore promotes proliferation. 
Figure 2: Gleason grade patterns for prostate cancer lesions
(A) Gleason grade 1 (arrows outline an individual prostate acinus; original magniﬁ cation ×40. (B) Gleason grade 2 
(original magniﬁ cation ×40). (C) Gleason grade 3 (arrows show a small amount of individual cell inﬁ ltration into 
surrounding stroma; original magniﬁ cation ×100). (D) Gleason grade 4 (increased stromal invasion; white arrows 
show some areas of gland fusion and poorly deﬁ ned lumens; green arrow shows one of a few areas in which 
Gleason pattern 3 is present; original magniﬁ cation ×40). (E) Gleason grade 5 (solid sheets of cells with no 




e512 www.thelancet.com/oncology   Vol 13   November 2012
Personal View
Although the association of ERG gene rearrangements 
and aggressive prostate cancer remains controversial, that 
such rearrangements have a sub stantial role in the 
transformation of some cancers is becoming apparent. 
Since TMPRSS2–ERG fusions lead to frequent changes in 
the ERG proto-oncogene in early-stage prostate cancer, 
investigation of this fusion in preneoplastic cells and 
multifocal lesions from the same patient has the potential 
to deﬁ ne its role in prostate cancer onset, progression, and 
heterogeneity. In fact, evidence suggests that ERG protein 
expression can be used as a surrogate marker for ERG 
genetic rearrangements. In a cross-sectional study27 in 
which individual cancers from radical prostatectomy 
specimens with two to three tumour foci of various sizes 
and grades were analysed, the researchers established that 
ERG protein expression is signiﬁ cantly increased in 
tumours with large volumes and high Gleason grade, 
presumably as a result of this transcription factor 
promoting tumour growth and proliferation.
However, other evidence emphasises the uncertainty 
about the role of this particular gene fusion in prostate 
cancer development and progression. Furusato and 
colleagues28 showed that TMPRSS–ERG fusions reside 
predominantly in the index lesion, but are also present in 
some secondary lesions and some histologically benign 
areas of prostate. Others29 have shown a strong relation 
between expression of TMPRSS2–ERG fusion mRNA 
isoforms and pathological measures of clinical outcome 
(seminal vesicle invasion, extracapsular exten sion) in 
lesions from radical prostatectomy specimens. The same 
researchers also reported expression of the gene fusion 
in benign glands of the prostate.
Hallmark ﬁ ve: sustained angiogenesis
Neoangiogenesis is a normal physiological process that 
takes place during embryonic development and wound 
healing. The process is also necessary for tumours to 
break through the volume threshold of 1 mm diameter, 
since tumours larger than this cannot rely on the 
diﬀ usion of oxygen from existing vessels.
Angiogenesis is probably necessary to support accel-
erated tumour growth, since the metabolic needs of the 
tumour must be met by an adequate blood supply.30 
Prostate cancer cells have the ability to produce several 
factors that promote new vessel formation. Malignant 
prostate cells secrete proangiogenic molecules such as 
VEGF, ﬁ broblast growth factor 2, TGFβ, and cyclo-
oxygenase-2. So the question arises, does this forced 
vascular proliferation occur preferentially in high-grade 
lesions or is it a transformation that is permissive for 
proliferation and dediﬀ erentiation of prostate cancer 
cells? Raised VEGF and increased microvessel density 
are related to a poor prognosis in prostate cancer,31 and a 
close association exists between the two. Moreover, this 
association seems to be more pronounced in high-grade 
and large tumours than in low-grade and small tumours.32 
In a well designed study, Mucci and col leagues33 
established that poorly diﬀ erentiated tumours showed 
increased microvessel density and irregularity of the 
blood vessel lumen with reduced vessel size. After 
20 years of follow-up, 44 of 572 men had either developed 
bone metastases or had died of cancer. Men with tumours 
that had the smallest vessel diameter at inclusion were 
six times more likely (95% CI 1·8–20·0) to develop 
metastatic prostate cancer or to die from the disease. 
Additionally, another subgroup was identiﬁ ed that had 
even greater propensity for clinical progression; men 
who had irregularity of vessel diameter were 17 times 
more likely (95% CI 2·3–128) to reach the same two 
endpoints. Microvessel density itself was not linked to 
cancer-speciﬁ c mortality after results were adjusted for 
clinical factors.33
Other factors are either required or facilitate new vessel 
formation. Pasquli and colleagues34 have added to the 
evidence that the drivers for new vessel formation are 
over-represented in prostate cancers that have high-grade 
elements. They showed a substantial upregulation of 
endocrine gland-derived VEGF or prokineticin protein 
expression in higher-grade lesions compared with 
exclusive Gleason pattern 3 lesions. Killingsworth and 
Wu35 provided further insight, elucidating the mech-
anism by which new vessel formation takes place. The 
researchers studied pericyte interactions that were 
associated with new vessels using transmission electron 
microscopy. The interaction of endothelial cells from 
blood vessels with pericytes is essential for the process 
of prostate cancer neoangiogenesis, with pericytes 
increasingly acknowledged as molecular regulators of 
angiogenesis. Pericyte distribution was mapped from 
Original Gleason system Modiﬁ ed system*
Gleason 
grade 1
Very well diﬀ erentiated, small, closely packed, 
uniform glands in essentially circumscribed 
masses
Circumscribed nodule of closely packed but 
separate, uniform, rounded-to-oval, 
medium-sized acini (larger glands than pattern 3)
Gleason 
grade 2
Similar to pattern 1, but with moderate 
variation in size and shape of glands and more 
atypia in individual cells; cribriform pattern 
might be present—still essentially 
circumscribed, but more loosely arranged
Similar to pattern 1, fairly circumscribed, 
although a little inﬁ ltration might be seen at the 
edge of the tumour nodule; glands are more 




Similar to pattern 2, but substantial 
irregularity in size and shape of glands, with 
tiny glands or individual cells invading stroma 
away from circumscribed masses, or solid 
cords and masses with easily identiﬁ able 
glandular diﬀ erentiation within most of them
Discrete glandular units; typically smaller 
glands than seen in pattern 1 or 2; inﬁ ltrates in 
and among non-neoplastic prostate acini; 
substantial variation in size and shape; 




Large, clear cells growing in a diﬀ use pattern 
that resembles hypernephroma; might show 
gland formation
Fused microacinar glands; ill deﬁ ned glands with 
poorly formed glandular lumina; large cribriform 




Very poorly diﬀ erentiated tumours; usually 
solid masses or diﬀ use growth with little or no 
diﬀ erentiation into glands
Essentially no glandular diﬀ erentiation—
composed of solid sheets, cords, or single cells; 
comedocarcinoma with central necrosis 
surrounded by papillary, cribriform, or 
solid masses
*Modiﬁ ed system grades deﬁ ned by the International Society of Urological Pathology.14
Table: Original Gleason scoring system and the 2005 modiﬁ ed system
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α-smooth-muscle-actin-positive immune-stained histo-
logical sections and quantiﬁ ed by image analysis. 
Exclusive Gleason pattern 3 lesions had a microvessel 
pericyte density score that could not be distinguished 
from benign prostate tissue, by contrast with the scores 
of higher-grade lesions.
Hallmark six: tissue invasion and metastasis
The potential for invasion into adjacent anatomical 
structures and spread to distant sites are key attributes 
of cancer cells. Most manifestations of prostate cancer 
do not have either of these properties.
Evidence exists that suggests the absence of invasive and 
metastatic behaviour in most prostate lesions. For 
example, when individual prostate lesions derived from 
one patient’s primary prostate cancer specimen were 
implanted into mice, only one lesion out of three showed 
characteristics of local invasion and eventually formed 
metastases.36 This work reminds us that as well as 
histological heterogeneity within any one prostate lesion 
there are, within the cancer, distinct elements with a 
range of biological potentials. The characteristics of those 
elements that are capable of metastatic spread are 
relevant to our argument. Elements that are permissive 
for cell migration seem to be comparatively overexpressed 
in higher-grade lesions than in exclusive Gleason 
pattern 3 lesions. The chemokine receptor CXCR4 is one 
of those elements that are upregulated in localised, high-
grade Gleason pattern 4 lesions compared with Gleason 
pattern 3 lesions. This G-protein-coupled transmembrane 
receptor has a key role in the directional migration of 
cancer cells to speciﬁ c metastatic sites in response to its 
ligand CXCL12. Additionally, CXCR4 upregulation has 
been associated with lymph node and bone metastasis in 
prostate cancer, possibly through activation of the RAS 
oncogene family member RAP1A, the expression of 
which is also upregulated in Gleason pattern 4 lesions 
relative to those containing only Gleason pattern 3. 
Investigators of other studies have suggested that hypoxia 
induces CXCR4 expression in tumour cells via hypoxia-
inducible factor 1α.37,38 Large volume tumours are much 
more likely to have central hypoxic areas than are small 
volume tumours. Expres sion of CXCR4 on the tumour 
cell membrane allows the cancer cells to migrate or 
metastasise away from the area of low oxygen tension, 
down a CXCL12 concentration gradient, to areas of high 
oxygen concentration. The ligand CXCL12 is secreted at 
especially high concen trations by lymph node and bone 
marrow stromal cells.
Most men have two to three distinct tumour foci in 
their prostate at presentation. Most of the tumour 
burden is usually contained within one of these foci. 
This dominant tumour by volume (which is strongly 
associated with grade) has been termed the index lesion 
because of its putative biological potential. Wise and 
colleagues39 were possibly the ﬁ rst to develop this idea. 
They showed that Gleason pattern 4 and 5, volume of 
the largest tumour, and lymphovascular invasion were 
intraprostatic independent predictors of clinical prostate 
cancer progression. Other researchers40 have noted that 
80% of secondary foci are smaller than 0·5 cm³ and 
have the same volume distribution as do tumours found 
incidentally in patients that undergo cystoprostatectomy 
for bladder cancer. In most other solid cancer models of 
progression, tumour volume is a key determinant. The 
same is true, it would seem, of the prostate, although 
the evidence to support this assertion has taken some 
time to accumulate. Tumour volume has been proposed 
to be associated with prostate-speciﬁ c antigen (PSA) 
recur rence41 and prostate lesions smaller than 0·5 cm³ 
are almost always clinically insigniﬁ cant because of the 
long doubling times of such lesions.42 Several authors43,44 
have proposed that the threshold for signiﬁ cance of 
volume be placed higher, at 1·2 cm³, on the basis of data 
from the European large-scale ran domised prostate 
cancer screening trial, in which volume thresholds of 
insigniﬁ cant disease were calculated on the basis of 
models of lifetime risk estimates of prostate cancer 
diagnosis in screened and non-screened participants. 
The investigators showed that the minimum threshold 
tumour volume of the index lesion and total tumour 
were 0·55 cm³ and 0·70 cm³, respectively. However, 
after accounting for tumour stage and grade, the 
threshold volumes for the index tumour and total 
tumour were 1·3 cm³ and 2·5 cm³, respectively.43,44
A strong association also seems to exist between 
pathological and staging measures of poor prognosis 
(extracapsular invasion, seminal vesicle invasion, metas-
tases) and individual cancer lesion volumes. Lesions 
measuring 0·5 cm³ or more had a one in ten chance of 
capsular invasion, whereas lesions measuring 4·0 cm³ 
or more had a one in ten chance of seminal vesicle 
invasion. Lesions measuring 5·0 cm³ or more had a one 
in ten chance of metastases.45 Volume is an important 
determinant of grade (or vice versa); Gleason pattern 4 
or higher is very rare in lesions that are not attributed 
index status.46 If the volume of a lesion is a key attribute 
of progression, as it seems to be,47 then multiplicity for 
any given overall tumour volume within a prostate 
should be a good prognostic sign. In other words, if 
2 cm³ of tumour is distributed fairly equally among ﬁ ve 
separate lesions, the mean lesion volume will be less 
than 0·5 cm³. If, on the other hand, the cancer was 
unifocal (seen in about one in ﬁ ve men who present 
with prostate cancer), then the mean tumour volume 
will equate to the overall tumour volume—ie, 2 cm³. The 
primacy of the index lesion as a determinant of 
progression seems to hold.
The next question in relation to the volume of speciﬁ c 
prostate cancer foci is about the biological potential of 
these small lesions. Tumour doubling times are the 
means by which this potential can be estimated. Schmid 
and colleagues48 have reported that 79% of men with 
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previously untreated prostate cancer of all clinical stages, 
who had serial PSA measurements during a period of at 
least 12 months, had a tumour doubling time greater 
than 24 months. Primary tumour volumes that theor-
etically lead to distant metastases tend to be at least 4 cm³ 
in volume.49 As such, with an estimated tumour volume 
doubling time of 2 years, it would take about 6 years for a 
0·5 cm³ lesion to reach a volume of 4 cm³.
Although overwhelming evidence suggests that small 
tumours are very safe from a biological perspective, there 
remain some anomalies that remind us that our 
understanding is far from complete. Local invasion does 
not seem to be as closely linked to cancer foci volume 
as are metastases. Up to one in four tumours that 
show capsular invasion can be identiﬁ ed as non-index 
lesions,50 and although tumours that are locally invasive do 
need to achieve some volume threshold, they do not 
necessarily have to be very large.51 In fact, circulating 
tumour cells and occasionally lymph-node metastases 
have been reported in men who have lesions of 0·2 cm³ in 
volume.52 In a series of 239 patients with tumour volumes 
of less than 0·5 cm³, investigators showed that 43 were 
poorly diﬀ erentiated, 11 had extracapsular extension, six 
had positive surgical margins, two had positive lymph 
nodes, and seven progressed within 5 years.53 Greene and 
coworkers54 assessed DNA ploidy status, which is an 
independent prognostic factor for localised prostate cancer. 
Of 141 separate lesions in 68 patients, the investigators 
reported that 15% of those 0·01–0·1 cm³ and 31% of those 
0·11–1·0 cm³ in volume were non-diploid. Thus, tumour 
volume in itself did not adequately predict the biological 
potential of prostate cancer and so should be combined 
with other factors, predominantly Gleason grade.
The molecular association of individual lesions with 
lymph node metastases has added more force to the 
argument that, despite multifocality, prostate cancer 
disease progression is likely to be related to lesions that 
meet some minimum grade and volume thresholds. 
TMPRSS–ERG gene fusions seen in lymph node 
metastases are also found in the index lesion and not in 
small, low-grade satellite lesions55 or secondary high-
grade and high-volume lesions.56 Results of one 
important study57 showed that metastatic deposits taken 
from men in a rapid autopsy protocol shared one 
common cell of origin. However, the question of whether 
the metastatic clone originated from the index lesion is 
something that was not possible to address in this study 
because of the nature of the men from whom the tissue 
samples were taken (ie, they had been through ﬁ rst-line 
and second-line hormonal therapies in addition to 
chemotherapy in some instances, so the prostates were 
small and ﬁ brotic, which made the delineation of 
individual lesions impossible).58 Grasso and colleagues59 
also noted the monoclonal origin of lethal, castrate-
resistant prostate cancer by sequencing the exomes of 
metastatic deposits in 50 lethal, heavily pretreated 
metastatic cancers obtained at autopsy.
Epidemiological evidence also supports the assertion 
that most prostate lesions, especially those of low volume 
and low Gleason grade, currently called cancer, do not 
show tissue invasion and eventual metastases. Evidence 
from post mortem studies has shown a frequency of one 
in three so-called prostate cancers in men who died of 
other causes. Similar frequencies are seen on assessment 
of prostates taken from cystoprostatectomy specimens 
from men who have undergone surgery for high-risk or 
invasive bladder cancer.40 Therefore, since a third of men 
have prostate cancer that will not aﬀ ect them in their 
lifetimes, it is unsurprising that small, low-grade lesions 
have low (or possibly absent) malignant potential.
This argument is lent support by ﬁ ndings from long-
term radical prostatectomy outcome series. For example, 
Eggener and coworkers60 showed that, of 9775 men who 
had Gleason 3 pattern in isolation conﬁ rmed on radical 
whole-mount prostatectomy specimens, only three died 
of prostate cancer in a 15 year period. In fact, when 
these three patients were reviewed, a small amount of 
Gleason pattern 4 was seen.1 This ﬁ nding cannot merely 
be accounted for by the success of surgery itself and is 
strong evidence that exclusive Gleason pattern 3 
prostate lesions are not a metastatic phenotype. 
Others61,62 have reported similar ﬁ ndings in smaller 
cohorts of patients, but using biochemical recurrence as 
a surrogate out come measure.
The scientiﬁ c literature about the advantages and 
disadvantages of active surveillance also helps the 
understanding of whether low-volume, low-grade dis-
ease behaves in a malignant way. Warlick and colleagues63 
investigated whether curability after surgery, which 
they deﬁ ned as surgical pathological characteristics that 
would generally confer a greater than 75% chance of 
remaining biochemically recurrence-free at 10 years, 
was aﬀ ected if treatment was delayed.64 In other words, 
is the window of opportunity for cure—something that 
con cerns patients and physicians alike when considering 
active surveillance—lost in men with small, low-grade 
disease who have delayed curative treatment? After 
comparing the burden of supposedly incurable cancer 
among patients undergoing delayed surgery at a median 
time of 26·5 months after diagnosis with that in patients 
undergoing immediate surgery (who would have been 
eligible for active surveillance) the investigators reported 
no association between adverse pathological changes on 
whole-mount specimens and the time period between 
diagnosis and surgery. Clinical experience with active 
surveillance suggests that an estimated risk of metastasis 
exists of less than 1% at 2–8 years64 and disease-speciﬁ c 
mortality of 1% at 8 years in men undergoing surveillance 
for low-risk disease as classiﬁ ed by a diagnostic trans-
rectal ultrasound-guided biopsy. Early outcomes in men 
with intermediate-risk disease managed by active 
surveillance have also been encouraging.65 Results of 
research that has assessed active surveillance have 
shown that all prostate cancer-related mortality occurred 
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in men who had been reclassiﬁ ed as higher risk and who 
were oﬀ ered radical treatment. Therefore, reclassiﬁ cation 
of disease risk and subsequent radical treatment is likely 
to have occurred because of undersampling of the 
prostate rather than because of true progression. In 
other words, when compared with a more rigorous 
sampling strategy, transrectal ultrasound-guided biopsy 
undergrades and understages disease as a result of 
random and systematic errors in sampling the prostate.66
Clinical implications
When prostate cancer is identiﬁ ed from biopsies, 
the psychological connotations associated with having 
cancer mean that many men choose or are advised to 
undergo radical treatment that they stand little chance of 
beneﬁ ting from.67 Most clinicians advising patients 
know that exclusive Gleason pattern 3 carries very little 
lifetime risk to the patient, but many still recommend 
radical treatments that carry high toxicity proﬁ les. The 
principal driver remains uncertainty. More speciﬁ cally, 
this uncertainty is in relation to the precision of risk 
stratiﬁ cation. The absence of precision means that the 
attribution of low risk is insecure in about one in three 
men who are deemed to be at low risk (exclusive Gleason 
pattern 3 disease), but in fact are not. If we could 
accurately identify men with Gleason pattern 3 lesions 
in isolation, these men would be very likely to be at 
much lower (possibly negligible) risk of death from 
prostate cancer than men previously attributed a Gleason 
pattern 3 diagnosis of cancer. If this situation came to 
pass, we might be in a position to reclassify exclusive 
Gleason pattern 3 lesions to a term that substitutes the 
word cancer for something else, such as IDLE.3 Such a 
term would seem to be appropriate; if low-volume, low-
grade lesions were reclassiﬁ ed as non-cancer or IDLE 
lesions and this change met with widespread pro-
fessional acceptance, the immediate implications for 
clinical practice would be profound.
First, research into novel detection strategies and 
therapies is likely to need substantial rethinking. 
At present, new tissue and imaging biomarkers are 
usually tested for their ability to ﬁ nd all cancer on the 
basis of the transrectal ultrasound-guided biopsy. In 
fact, hundreds of millions of pounds have been spent on 
the discovery of an elusive biomarker during the past 
two to three decades, on the premise that the outcomes 
from the transrectal ultrasound-guided biopsy are the 
gold standard. However, this test detects clinically 
insigniﬁ cant, possibly non-malignant lesions (which 
incorrectly designates the patient a true positive). A 
third of all men diagnosed with prostate cancer are 
estimated to have clinically insigniﬁ cant disease.64,68,69 
Furthermore, transrectal prostate biopsies can miss a 
clinically signiﬁ cant cancer that is likely to progress and 
metastasise within a man’s lifetime (which incorrectly 
designates the patient a true negative). 40% of men who 
test negative on biopsy are estimated to have cancer;68,70 
of these, a third have clinically signiﬁ cant cancer based 
on lesion volume and presence of high grade.69
Second, a recalibration of what is deemed cancer is 
likely to substantially reduce the overdiagnosis and 
overtreatment burdens with which we are all familiar. 
Clinicians could rely on tests that target measurable 
malignant disease rather than attempting to ﬁ nd all 
lesions. Imaging intrinsically cannot detect every focus 
of Gleason pattern 3. A recalibration of what is deemed 
malignant would mean that we should not expect these 
imaging modalities to do so. The performance charac-
teristics of multiparametric MRI, for example, coupled 
with an intensive sampling strategy, in being able to rule 
out 0·5 cm³ lesions with a negative predictive value of 
about 90–95%, is arguably an ideal test.71 A large 
multicentre study is in progress that is assessing the 
reproducibility of such imaging in men at risk before any 
biopsy, against a reference standard that can be applied 
in all men and not only those who undergo surgery 
(NCT01292291). The key with imaging is that it could 
provide an accurate volume with indicators of high 
Gleason grade before biopsy and act as a triage test to 
identify men who need biopsies, which would allow men 
with no clinically signiﬁ cant cancer to avoid entering the 
diagnostic pathway altogether.72
Third, when compared with other solid organ malig-
nancies, prostate cancer is an outlier. Treatments for 
breast, renal, thyroid, liver, and pancreatic cancers all 
include tissue-preserving therapies, if appropriate, which 
are dependent on location and burden of the cancer. 
These specialties in oncological surgery de veloped tissue 
preservation, as opposed to Halsted prin ciples for wide 
surgical margins, because of upstream diagnostic 
methods that rely on identifying measurable (by pal-
pation or imaging) disease that can undergo targeted 
sampling followed by targeted treatment. The transrectal 
ultrasound-guided prostate biopsy has led to the reverse 
approach for prostate cancer. Random and blind 
sampling has forced our hands as clinicians, so that we 
have to apply radical whole-gland principles because the 
exact disease statuses of regions of the prostate are 
Search strategy and selection criteria
We searched PubMed and Medline for relevant publications 
from the past 10 years (Jan 1, 2002 to April 16, 2012), and 
supplemented the results of our search with key articles from 
before this period when appropriate. Publications were 
selected for their ﬁ ndings of diﬀ erences between lesions in 
each of the six hallmarks of cancer criteria. We used the search 
terms “prostate cancer” AND “multifocal” OR “index lesions/
tumo(u)r OR “secondary lesions/tumo(u)r”. Separate searches 
with these terms were supplemented by those with terms 
related to each hallmark of cancer. Searches were 
supplemented by authors’ personal bibliographies. Only 
articles published in English were included.
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unknown. So, if multifocality is overlooked in other 
organs by targeting only the measurable index lesion—
that which is largest by size and has elements of the 
highest grade—that targeting these lesions in prostate 
cancer might be suﬃ  cient to lead to acceptable, possibly 
equivalent, cancer control rates to whole-gland therapy is 
a reasonable hypothesis. In prostate cancer, one strategy 
could be to target lesions that meet widely acceptable 
thresholds for clinically signiﬁ cant cancer. Focal therapy 
certainly leads to reduced genitourinary and rectal side-
eﬀ ects, if the results of early prospective studies are 
reproducible across populations, centres, and 
surgeons.73–75 However, the key will be to design 
longitudinal cohort and comparative eﬀ ectiveness 
studies that assess medium-term and long-term cancer 
control. Such research will need to focus on the natural 
history of untreated benign and low-volume, low-grade 
prostate lesions.
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